is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 74 locations throughout 51 countries around the world, and has approximately 14,000 employees, including 282 employees related to the acquisition of Liquent. For more information about PAREXEL International visit www.PAREXEL.com
PAREXEL is a registered trademark of PAREXEL International Corporation, Perceptive Informatics is a trademark of Perceptive Informatics, Inc., and Liquent is a registered trademark of Liquent, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc., Liquent, Inc. or their respective owners and are hereby acknowledged.
This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand.
For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "woul
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 Related medicine technology :1
|SOURCE PAREXEL International Corporation|
Copyright©2012 PR Newswire.
All rights reserved
. PAREXEL Chief Operating Officer Dr. Mark A. Goldberg Receives Special Recognition Award2
. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results3
. Parexel Invites Public To Listen To Live Webcast Of Its Investor Day May 31, 20124
. PAREXEL Chairman And CEO To Ring The Bell At The NASDAQ Stock Market Opening5
. PAREXEL International Issues Earnings Guidance In Conjunction With Investor Day6
. PAREXEL International To Present At NASDAQ OMX Investor Conference7
. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2012 Earnings Release and Conference Call8
. PAREXEL And Korea Drug Development Fund Announce Alliance To Accelerate Global Drug Development And Commercialization9
. PAREXEL Launches The PAREXEL BioPharm Unit To Meet The Critical Development Goals Of Small And Mid-Sized Biopharmaceutical Companies10
. PAREXEL Strengthens Outcomes Research Capabilities To Help Biopharma Meet Commercialization Goals11
. PAREXEL International to Present at Robert Baird Healthcare Conference